In modern medicine, timing is everything. Yet most healthcare systems are built to act only after something has already gone wrong. Dr. Severence MacLaughlin has built his life around challenging that premise. Long before artificial intelligence became a global buzzword, MacLaughlin was studying large-scale datasets and asking an uncomfortable question: Why do we wait for people to get sick before we intervene?
That question now drives his work at DeLorean AI, a Palm Beach-based predictive medicine company focused not on treating disease, but on anticipating it.
A Childhood That Shaped a Philosophy
MacLaughlin did not grow up in research hospitals or tech corridors. He was raised on a working sheep and turkey farm in rural Rhode Island. Hard work was expected. Waste was unacceptable. If something could be fixed early, you fixed it before it became a bigger problem. That mindset stayed with him.
After graduating from Bishop Hendricken High School, he applied to one university, Cornell University, and was accepted. His academic path eventually led him to Australia, where he completed his PhD while working with massive datasets that required mainframe computing power. He became fluent in complex systems. But what struck him most was not the technology. It was the inefficiency he saw in real-world institutions. Healthcare in particular troubled him. “We had the data,” he says. “We just were not using it to change outcomes.”
The Breaking Point
For years, MacLaughlin advised large organizations on analytics and artificial intelligence. He built companies. He held senior leadership roles. From the outside, it looked like success. Then his father died. Soon after, a close friend passed away as well.
The grief clarified something he could no longer ignore. In many chronic conditions, warning signs had existed long before diagnosis. The system had simply failed to act early enough. Modern medicine excels at crisis response. It struggles with foresight. MacLaughlin made a decision that would redirect his career. If predictive capability existed, it needed to be applied where it mattered most: human health.
The Case for Predictive Medicine
At DeLorean AI, the mission is not to replace physicians or automate care. It is to give clinicians earlier visibility into risk. The company’s platform focuses on five of the most burdensome chronic conditions in the United States: cardiovascular disease, chronic kidney disease, diabetes, COPD, and depression. These illnesses account for enormous cost, suffering, and preventable mortality.
By analyzing patterns across more than 80 million anonymized patient records, the system identifies subtle risk signals years before traditional clinical thresholds are crossed. It does not simply flag danger. It provides guidance on what to do next. Within the first 90 days of implementation, adverse outcomes have dropped by more than 27 percent. In settings where physicians act on the insights, hospitalization rates decline dramatically.
For MacLaughlin, those numbers represent something far more human. “Every avoided hospitalization is time given back,” he says. “Time with family. Time for recovery. Time for another milestone.”
A Moral Argument, Not Just a Technical One
MacLaughlin often frames predictive medicine not as innovation, but as responsibility. If artificial intelligence can detect disease progression earlier than the naked eye, failing to use it becomes an ethical question. Waiting for organs to fail, for blood sugar to spiral, or for depressive symptoms to escalate is no longer inevitable. It is preventable.
Healthcare, he believes, must move from episodic care to continuous awareness. The shift requires more than software. It demands a cultural change inside institutions that have long been structured around billing events and acute episodes rather than long term prevention. DeLorean AI is one attempt to accelerate that shift.
Looking Beyond Institutions
While the company currently works closely with healthcare systems, MacLaughlin envisions a future where predictive insights are not confined to hospital walls. He believes individuals should understand their own risk trajectories long before symptoms appear. The long term goal is a world where patients are active participants in prevention, armed with foresight rather than fear.
“Preventive care should not start when damage is already visible,” he says. “It should start when the outcome can still be changed.”
From Pasture to Prediction
MacLaughlin’s journey from a farm in Rhode Island to leading a predictive medicine company is not a story about disruption for its own sake. It is about timing. On a farm, you learn quickly that small problems grow if ignored. Healthcare, he argues, is no different. The tools now exist to see what is coming. The real question is whether the system is willing to look.
For Dr. Severence MacLaughlin, the future of medicine is not reactive. It is anticipatory. And the difference between the two may be measured not in revenue or innovation headlines, but in years of life quietly preserved.
